Capacity Worries Fade for Biomanufacturing

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-07-02-2003, Volume 27, Issue 7

The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.

Related Content:

OutsourcingOutsourcing OutlookPharmaceutical Technology-07-02-2003
How New Regulations Are Impacting Pharmaceutical Manufacturing Facility Design
Annex 1 Alignment: Addressing Contamination Control and Assessing Risk
Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy